查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1990114

電腦輔助藥物發現市場：按分子類型、導入模式、定價模式、類型、技術、應用和最終用戶分類——2026-2032年全球市場預測

Computer-aided Drug Discovery Market by Molecule Type, Deployment Model, Pricing Model, Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

電腦輔助藥物發現市場預計到 2025 年將達到 44.9 億美元，到 2026 年將成長到 49 億美元，到 2032 年將達到 88 億美元，複合年成長率為 10.08%。

主要市場統計數據
基準年 2025 44.9億美元
預計年份：2026年 49億美元
預測年份 2032 88億美元
複合年成長率 (%) 10.08%

人工智慧驅動的整合工作流程、雲端規模資料平台和跨學科夥伴關係正在加速藥物候選物的識別，並改變轉化決策。

先進計算技術、大規模生物資料集和演算法創新的融合，正引領藥物發現進入一個新時代。計算方法不再是孤立的任務，而是成為貫穿整個流程的關鍵促進因素，影響目標選擇、先導化合物篩選、先導化合物最佳化以及臨床前安全性評估。因此，各機構正在重新思考如何設計藥物發現工作流程、組建團隊以及建立外部夥伴關係，以更快地產生假設並進行更具預測性的In Silico評估。

物理建模、衍生設計和分子模擬精確度的提高，正在策略性地重新定義早期藥物發現的限制，並推動探索新的治療方式。

電腦輔助藥物發現領域正經歷一場變革，其驅動力既來自功能的提升，也來自不斷發展的產業實踐。機器學習架構和基於物理的建模技​​術的進步提高了In Silico預測的可解釋性和可靠性，使研究團隊能夠更有信心地確定實驗的優先順序。同時，可互通資料標準和聯邦學習方法的普及降低了多機構合作的門檻，同時保障了資料隱私和來源資訊的安全。

檢驗美國關稅政策在 2025 年對藥物研發領域供應鏈動態、計算工具採購和國際合作的累積影響。

到了2025年，美國實施的貿易政策措施對電腦輔助藥物發現生態系統內的採購、部署和全球合作模式產生顯著影響。關稅及相關貿易措施加強了對專用硬體和軟體供應鏈的審查，促使各機構重新評估供應商關係，並考慮關鍵計算資產的本地化策略。這種重新評估正在影響總體擁有成本、計劃進度以及跨境研究舉措的靈活性。

從細分市場的角度深入了解分子類型、部署模型、定價結構、最終用戶、解決方案類型、底層技術和應用主導的部署模式。

一套精細的細分框架揭示了產品和服務實施的不同面向如何影響能力部署和價值獲取。基於分子類型，生物製劑和小分子藥物之間有明顯的差異，二者對計算的需求截然不同。生物製劑的工作流程著重於序列分析、結構建模和免疫抗原性預測，而小分子藥物計畫則優先考慮配體-蛋白質相互作用、理化性質最佳化和合成可行性評估。這些不同的需求導致了技術組合和團隊組成的多樣性。

區域分析重點關注美洲、歐洲、中東和非洲以及亞太地區的趨勢，這些趨勢會影響人才流動、監管協調和基礎設施投資重點。

區域趨勢對電腦輔助藥物發現能力的演進產生了決定性影響，每個區域都有獨特的優勢和限制因素，這些因素共同塑造了策略規劃。在美洲，生物製藥研究中心的集中、創業投資的便利性以及技術供應商的密集生態系統正在加速先進運算平台的普及應用。這種環境有利於加速商業化進程，並促進藥物發現團隊與轉化開發夥伴之間的緊密合作。

本報告著重分析塑造產業格局的平台差異化、服務組合、夥伴關係和智慧財產權策略，並探討競爭對手和合作夥伴的發展趨勢。

在電腦輔助藥物發現領域，企業行為呈現產品差異化、平台整合和策略夥伴關係的特徵。主要企業正著力打造整合式資料管理、建模引擎和視覺化工具的平台，進而降低跨領域團隊採用電腦輔助方法的門檻。同時，一些企業則專注於生成化學、高精度分子動力學或專業ADMET預測模組等細分領域的能力，以滿足特定領域的需求並建立自身強大的專業知識。

為產業領導者提供實用建議，優先考慮職能投資、合作模式、管治結構和人才策略，以建立永續的競爭優勢。

產業領導者在將基於計算化學的藥物發現流程整合到核心研發中時，應採取務實且循序漸進的方法。優先投資解決轉化研究中的直接瓶頸，例如提高ADMET性質的預測準確性以及加強標靶檢驗流程。為確保計算結果的持續可靠性，應將這些投資與管治框架結合，該框架要求結果可重複、模型文檔化以及定期與實驗結果進行回測。

一種透明的跨學科調查方法，說明了資料來源、專家檢驗、建模技術以及為確保可重複性和分析嚴謹性而採取的措施。

本研究採用跨學科調查方法，結合了專家的訪談、二手文獻的整合以及對代表性工具和工作流程的技術評估。一手資料包括與藥物研發科學家、平台工程師和採購專家的結構化對話，這些對話構成了對採用障礙、管治實踐和組織準備進行判斷的基礎。二級資訊來源包括同行評審文獻、預印本和行業白皮書，從而對技術能力和預測性能方面的證據進行了多方面的檢驗。

這份簡明扼要的結論結合了策略見解、風險因素和前瞻性考慮，旨在幫助組織應對快速發展的電腦輔助藥物發現生態系統。

總而言之，電腦輔助藥物發現已從一套輔助工具發展成為一項策略支柱，重塑了假設的生成、優先排序和檢驗。機器學習、分子模擬和數據工程等領域的技術進步，結合可靠的實驗檢驗，提高了預測準確性並降低了轉換風險。那些將管治、人才和籌資策略與這些能力結合的組織，將更有利於加速藥物發現週期並提高資源配置效率。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按分子類型分類的電腦輔助藥物發現市場

  • 生物製藥
  • 低分子化合物

第9章：電腦輔助藥物發現市場：依部署模式分類

  • 基於雲端的
  • 現場

第10章：電腦輔助藥物發現市場：依定價模式

  • 計量收費
  • 永久許可
  • 訂閱

第11章：電腦輔助藥物發現市場：按類型分類

  • 服務
    • 諮詢
    • 執行
    • 研究外包
    • 支援和維護
  • 軟體
    • 數據分析
    • De Novo 設計
    • 分子建模
      • 基於配體的設計
      • 基於結構的設計
    • QSAR建模
    • 虛擬篩檢

第12章：電腦輔助藥物發現市場：依技術分類

  • ADMET預測
  • 生物資訊學
    • 功能基因體學
    • 序列分析
  • 化學資訊學
    • 圖書館設計
    • QSAR建模
    • 滑板跳躍
  • De Novo 設計
  • 分子建模

第13章：電腦輔助藥物發現市場：按應用領域分類

  • 臨床試驗支持
  • 發現鉛
  • 先導藥物最適化
  • 臨床前開發
  • 目標識別

第14章：電腦輔助藥物發現市場：依最終使用者分類

  • 學術機構及政府機構
  • 生技公司
  • 合約研究機構
  • 製藥公司

第15章：電腦輔助藥物發現市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：電腦輔助藥物發現市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：電腦輔助藥物發現市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國電腦輔助藥物發現市場

第19章：中國的電腦輔助藥物發現市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Accelrys, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Boehringer Ingelheim International GmbH
  • Chemical Computing Group Inc.
  • Dassault Systemes SE
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
Product Code: MRR-5D693B46C018

The Computer-aided Drug Discovery Market was valued at USD 4.49 billion in 2025 and is projected to grow to USD 4.90 billion in 2026, with a CAGR of 10.08%, reaching USD 8.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.49 billion
Estimated Year [2026] USD 4.90 billion
Forecast Year [2032] USD 8.80 billion
CAGR (%) 10.08%

How integrated AI-driven workflows, cloud-scale data platforms, and cross-disciplinary partnerships are accelerating candidate identification and transforming translational decision-making in drug discovery

The convergence of advanced computation, large-scale biological datasets, and algorithmic innovation is ushering in a new era for drug discovery. Computational methods are no longer confined to isolated tasks; they have become integral, end-to-end enablers that influence target selection, hit identification, lead optimization, and preclinical safety evaluation. As a result, organizations are rethinking how discovery workflows are designed, how teams are arranged, and how external partnerships are structured to take advantage of faster hypothesis generation and more predictive in silico evaluations.

This report synthesizes contemporary practice and emergent capabilities in computer-aided drug discovery, focusing on how methodologies, deployment choices, and enterprise behaviors collectively shape translational outcomes. The narrative emphasizes evidence-based developments such as greater fidelity in molecular simulations, the maturation of generative chemistry approaches, and the expanding role of cloud-scale compute in enabling iterative experimentation. By connecting technological capabilities to organizational implications, the intent is to equip research leaders and business executives with a clear framework for prioritizing investments and collaborations. Through careful analysis of technology trends, commercial behaviors, and regulatory touchpoints, the report frames where competitive advantage is likely to arise and what operational changes will be required to capture it.

Strategic emergence of physics-based modeling, generative design, and expanded molecular simulation fidelity that are redefining early discovery constraints and enabling novel modality exploration

The landscape of computational drug discovery is undergoing transformative shifts driven by both capability enhancements and evolving industry practices. Advances in machine learning architectures and physics-informed modeling have improved the interpretability and reliability of in silico predictions, enabling teams to prioritize experiments with greater confidence. Concurrently, the proliferation of interoperable data standards and federated learning approaches is reducing the friction of multi-institutional collaboration while preserving data privacy and provenance.

Organizationally, there is a clear pivot from siloed algorithmic experiments toward integrated discovery platforms that span biology, chemistry, and safety. This shift has prompted new partnership archetypes: long-term platform partnerships that embed vendor tools into internal workflows, and short-term specialist engagements that accelerate specific programs. Funding patterns and internal governance have also adapted, with entities establishing centres of excellence to manage model governance, reproducibility, and ethical use of data. These shifts collectively reduce time-to-decision and increase the likelihood that computational hypotheses translate into viable experimental programs.

Importantly, the technology maturation has broadened modality exploration; biologics and small molecules alike benefit from improved design tools. As a result, organizations are increasingly blending traditional medicinal chemistry expertise with computational scientists, creating hybrid teams that can both generate and validate complex hypotheses. This holistic realignment of skills, tools, and processes marks a fundamental change in how discovery programs are conceived and executed.

Examining cumulative effects of United States tariff policies in 2025 on supply chains, computational tool sourcing, and international collaboration dynamics within drug discovery

In 2025, trade policy actions introduced by the United States have had measurable implications for the procurement, deployment, and global collaboration patterns within computational drug discovery ecosystems. Tariffs and related trade measures have increased scrutiny over supply chains for specialized hardware and software, prompting organizations to reassess vendor relationships and consider localization strategies for critical computational assets. This reassessment has implications for total cost of ownership, project timelines, and the agility of cross-border research initiatives.

As a consequence, some organizations prioritized strategic stockpiling of compute capacity and sought multi-sourcing agreements to mitigate disruption risk. Others accelerated migration to cloud providers with distributed footprints to preserve access to GPU and TPU resources despite tariff-driven uncertainty. In parallel, international collaborations adapted by shifting contractual terms, redefining responsibilities for hardware provision, and embracing standardized containerization to ease replication across jurisdictions.

On the innovation front, tariff-related pressures encouraged tighter attention to software portability and open standard adoption, as teams aimed to avoid vendor lock-in that could be exacerbated by geopolitical trade frictions. Regulatory compliance and export controls also gained prominence in procurement decisions, with legal and compliance functions becoming active participants in technology evaluation. These cumulative effects have reshaped procurement strategies and collaborative models across the discovery ecosystem, reinforcing resilience as a central criterion for technology selection.

Segment-level intelligence into molecule types, deployment models, pricing structures, end users, solution types, enabling technologies, and application-driven adoption patterns

A nuanced segmentation framework reveals how different dimensions of offering and adoption influence capability deployment and value capture. Based on molecule type, differentiation emerges between biologics and small molecules with distinct computational requirements: biologics workflows emphasize sequence analysis, structural modeling, and immunogenicity prediction, whereas small molecule programs prioritize ligand-protein interactions, physicochemical property optimization, and synthetic accessibility assessments. These divergent needs drive varied technology mixes and team structures.

Based on deployment model, choices between cloud-based and on-premises delivery shape scalability and data governance trade-offs. Cloud-based approaches facilitate burst compute and collaborative federated learning, while on-premises deployments remain attractive for organizations with strict data residency or security constraints. Based on pricing model, organizations select between pay-per-use, perpetual license, and subscription arrangements to align financial exposure with project tempo and budget predictability.

Based on end user, adoption patterns differ across academic and government institutes, biotechnology companies, contract research organizations, and pharmaceutical companies, each prioritizing different combinations of flexibility, depth of customization, and regulatory alignment. Based on type, offerings split into services and software. Services encompass consulting, implementation, research outsourcing, and support and maintenance, providing hands-on expertise and operational integration. Software splits into data analytics, de novo design, molecular modeling, QSAR modeling, and virtual screening, with molecular modeling further divided into ligand-based design and structure-based design, reflecting the need for both top-down and bottom-up computational strategies.

Based on technology, capabilities include ADMET prediction, bioinformatics, chemoinformatics, de novo design, and molecular modeling. Within bioinformatics there is emphasis on functional genomics and sequence analysis, while chemoinformatics covers library design, QSAR modeling, and scaffold hopping. Based on application, use cases such as clinical trials support, lead discovery, lead optimization, preclinical development, and target identification illustrate how technology stacks are mapped to specific translational objectives. These segmentation lenses together inform where investments will yield the highest strategic return and how vendors can tailor their value propositions to distinct customer archetypes.

Regional intelligence highlighting Americas, Europe Middle East and Africa, and Asia-Pacific dynamics influencing talent flows, regulatory alignment, and infrastructure investment priorities

Regional dynamics critically influence the evolution of computational drug discovery capabilities, with each geography presenting distinct strengths and constraints that shape strategic planning. In the Americas, concentration of biopharma research centers, access to venture capital, and a dense ecosystem of technology vendors promote rapid adoption of advanced computational platforms. This environment supports accelerated commercialization pathways and close ties between discovery teams and translational development partners.

In Europe, Middle East & Africa, regulatory harmonization efforts and strong academic-industrial collaborations foster rigorous validation practices and a focus on reproducibility. Investment patterns in this region often emphasize public-private partnerships and infrastructure that supports precompetitive data sharing. These features contribute to robust methodological standards and collaborative networks that underpin long-term capability building.

In Asia-Pacific, rapid expansion of research infrastructure, significant public sector investment in biotechnology, and a growing pool of computational talent create an environment conducive to large-scale data initiatives and high-throughput screening programs. This region increasingly becomes a hub for both contract research activity and end-to-end discovery programs, leveraging cost efficiencies and scaling advantages. Across regions, differences in regulatory regimes, talent availability, and infrastructure maturity inform where organizations choose to centralize or decentralize capabilities, and those choices in turn shape partnership strategies and operational models.

Competitive and collaborative company insights focusing on platform differentiation, service portfolios, partnerships, and intellectual property strategies shaping the industry landscape

Company behavior in the computational discovery space is characterized by a mix of product differentiation, platform bundling, and strategic partnerships. Leading firms emphasize integrated platforms that combine data management, modeling engines, and visualization tools to lower the barrier for multidisciplinary teams to adopt computational approaches. Others focus on niche capabilities-such as generative chemistry, high-fidelity molecular dynamics, or specialized ADMET prediction modules-to serve domain-specific needs and develop defensible expertise.

Partnerships between software vendors and contract research organizations or laboratory automation providers are increasingly common, enabling end-to-end workflows that connect in silico hypothesis generation with rapid experimental validation. Intellectual property strategies often center on proprietary model architectures and curated datasets that provide predictive advantage, while open-source contributions and community benchmarks play a role in driving adoption and improving model transparency.

Service providers differentiate through consulting capabilities that translate algorithmic outputs into experimental plans, and through implementation teams that embed tools into existing discovery pipelines. Across the competitive landscape, companies that demonstrate interoperability, strong evidence of predictive performance, and a commitment to rigorous validation tend to secure longer-term engagements. Strategic alliances with academic institutions, clinical networks, and data custodians further expand access to curated datasets that enhance model training and validation, reinforcing a virtuous cycle of capability improvement for those organizations able to navigate complex partnership ecosystems.

Actionable recommendations for industry leaders to prioritize capability investments, partnership models, governance frameworks, and talent strategies for sustainable competitive advantage

Industry leaders should adopt a pragmatic, phased approach to integrating computational discovery into core R&D. First, prioritize capability investments that address immediate translational bottlenecks, such as improving prediction of ADMET properties or strengthening target validation pipelines. Align these investments with a governance framework that mandates reproducibility, model documentation, and routine back-testing against experimental outcomes to ensure sustained confidence in computational outputs.

Second, cultivate hybrid talent models that embed computational scientists alongside medicinal chemists and biologists to ensure hypotheses are both computationally sound and experimentally tractable. Invest in internal training programs and cross-functional rotations to accelerate knowledge transfer and reduce dependency on external consultants. Third, pursue partnership models that balance strategic platform commitments with the flexibility of specialist engagements, thereby preserving the ability to pilot new approaches while securing long-term integration where it delivers clear operational benefits.

Fourth, adopt procurement and architecture choices that mitigate geopolitical and supply chain risks, including multi-cloud strategies, software portability, and contractual clauses for continuity of service. Fifth, implement metrics and dashboards that translate computational performance into experimental productivity measures, thereby enabling continuous improvement and clearer ROI conversations with stakeholders. Together, these recommendations form an actionable roadmap for organizations aiming to derive consistent, reproducible value from computational drug discovery investments.

Transparent multidisciplinary research methodology describing data sources, expert validation, modeling approaches, and steps taken to ensure reproducibility and analytical rigor

This study employs a multidisciplinary research methodology combining primary expert interviews, secondary literature synthesis, and technical evaluation of representative tools and workflows. Primary inputs include structured conversations with discovery scientists, platform engineers, and procurement specialists, which informed judgment on adoption barriers, governance practices, and organizational readiness. Secondary sources encompassed peer-reviewed literature, preprints, and industry white papers to triangulate technological capabilities and evidence of predictive performance.

Technical evaluations involved reproducibility checks on benchmark datasets, assessment of model explainability features, and review of integration capabilities with laboratory information management systems and automation platforms. Wherever possible, findings were validated with case examples that illustrate how specific computational approaches impacted experimental throughput or decision-making processes. Ethical considerations and data governance practices were explicitly examined to ensure recommendations are implementable within prevailing regulatory regimes.

Analytical rigor was maintained through documented methodologies for data collection, transparent criteria for inclusion of tools and vendors in the study, and cross-validation of qualitative inputs. Limitations and assumptions are clearly articulated to support appropriate interpretation of conclusions and to enable organizations to adapt the approach to their unique contexts. This structured methodology ensures that the report's insights are both evidence-based and operationally relevant.

Concluding synthesis summarizing strategic takeaways, risk factors, and forward-looking considerations for organizations navigating a rapidly evolving computational drug discovery ecosystem

In summary, computational drug discovery has transitioned from a set of supporting tools to a strategic pillar that reshapes how hypotheses are generated, prioritized, and validated. Technological advances in machine learning, molecular simulation, and data engineering have enhanced predictive fidelity and reduced translational risk when paired with robust experimental validation. Organizations that align governance, talent, and procurement strategies with these capabilities are positioned to accelerate discovery cycles and increase the efficiency of resource allocation.

Key risk factors include geopolitical and trade-related perturbations to hardware and software supply chains, the potential for model overfitting without rigorous validation, and the need for clear governance around data provenance and ethical use. Nevertheless, institutions that invest in interoperable architectures, hybrid talent models, and strategic partnerships can convert these challenges into sources of resilience and competitive differentiation. The path forward requires disciplined experimentation, transparent measurement of computational performance against experimental outcomes, and a willingness to adapt organizational structures to sustain cross-disciplinary collaboration.

Ultimately, success in this evolving ecosystem will be defined by the ability to integrate computational insights seamlessly into laboratory decision-making, maintain reproducibility and model governance, and scale capabilities in a way that aligns with translational imperatives and regulatory expectations. This synthesis provides a foundation for executives to make informed decisions about where to focus resources and how to structure partnerships for long-term impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Computer-aided Drug Discovery Market, by Molecule Type

  • 8.1. Biologics
  • 8.2. Small Molecules

9. Computer-aided Drug Discovery Market, by Deployment Model

  • 9.1. Cloud-Based
  • 9.2. On-Premises

10. Computer-aided Drug Discovery Market, by Pricing Model

  • 10.1. Pay Per Use
  • 10.2. Perpetual License
  • 10.3. Subscription

11. Computer-aided Drug Discovery Market, by Type

  • 11.1. Services
    • 11.1.1. Consulting
    • 11.1.2. Implementation
    • 11.1.3. Research Outsourcing
    • 11.1.4. Support And Maintenance
  • 11.2. Software
    • 11.2.1. Data Analytics
    • 11.2.2. De Novo Design
    • 11.2.3. Molecular Modeling
      • 11.2.3.1. Ligand Based Design
      • 11.2.3.2. Structure Based Design
    • 11.2.4. QSAR Modeling
    • 11.2.5. Virtual Screening

12. Computer-aided Drug Discovery Market, by Technology

  • 12.1. ADMET Prediction
  • 12.2. Bioinformatics
    • 12.2.1. Functional Genomics
    • 12.2.2. Sequence Analysis
  • 12.3. Chemoinformatics
    • 12.3.1. Library Design
    • 12.3.2. QSAR Modeling
    • 12.3.3. Scaffold Hopping
  • 12.4. De Novo Design
  • 12.5. Molecular Modeling

13. Computer-aided Drug Discovery Market, by Application

  • 13.1. Clinical Trials Support
  • 13.2. Lead Discovery
  • 13.3. Lead Optimization
  • 13.4. Preclinical Development
  • 13.5. Target Identification

14. Computer-aided Drug Discovery Market, by End User

  • 14.1. Academic And Government Institutes
  • 14.2. Biotechnology Companies
  • 14.3. Contract Research Organizations
  • 14.4. Pharmaceutical Companies

15. Computer-aided Drug Discovery Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Computer-aided Drug Discovery Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Computer-aided Drug Discovery Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Computer-aided Drug Discovery Market

19. China Computer-aided Drug Discovery Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Accelrys, Inc.
  • 20.7. AstraZeneca PLC
  • 20.8. Bayer AG
  • 20.9. Bio-Rad Laboratories, Inc.
  • 20.10. Boehringer Ingelheim International GmbH
  • 20.11. Chemical Computing Group Inc.
  • 20.12. Dassault Systemes SE
  • 20.13. Eli Lilly and Company
  • 20.14. Gilead Sciences, Inc.
  • 20.15. GlaxoSmithKline PLC
  • 20.16. Merck & Co., Inc.
  • 20.17. Novartis AG
  • 20.18. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 253. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 254. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 257. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 258. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 290. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 292. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 293. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 295. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 296. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 297. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE,